The results of our meta-analysis demonstrated that treatment with PPARα/γ agonist, tesaglitazar, plus metformin reduced triglyceride (TG) concentrations in patients with type 2 diabetes, as compared to metformin treatment alone. This evidence concerns the gene PPARA and type 2 diabetes mellitus.